$75M Up Front, Potential $425M Later
Xencor Signs Amgen in Option Deal in Autoimmune Diseases
By Jennifer Boggs
Monday, January 10, 2011
About six months after inking a collaboration with MorphoSys AG for a Phase I-ready cancer candidate, antibody engineering firm Xencor Inc. signed an option deal with Thousand Oaks, Calif.-based Amgen Inc. targeting the autoimmune space.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.